Status:

COMPLETED

Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia

Lead Sponsor:

Cancer Research UK

Conditions:

Leukemia

Eligibility:

All Genders

Phase:

PHASE2

Brief Summary

RATIONALE: Drugs used in chemotherapy, such as fludarabine, cyclophosphamide, and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping th...

Detailed Description

OBJECTIVES: Primary * Assess the efficacy and safety of fludarabine, cyclophosphamide, and mitoxantrone hydrochloride with or without rituximab in patients with previously treated chronic lymphocyti...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Diagnosis of chronic lymphocytic leukemia requiring therapy
  • Previously treated with ≥ 1 chemotherapeutic regimen
  • PATIENT CHARACTERISTICS:
  • WHO performance status 0-2
  • Life expectancy ≥ 12 weeks
  • Creatinine clearance ≥ 30 mL/min
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile female patients must use effective contraception for 4 weeks before, during, and for 6 months after completion of study treatment
  • Fertile male patients must use effective contraception during and for 6 months after completion of study treatment
  • No history of anaphylaxis after exposure to rat or mouse-derived complementary-determining region (CDR)-grafted humanized monoclonal antibodies
  • No toxicity attributable to purine analogues (e.g., autoimmune hemolytic anemia, neurological toxicity, or allergy)
  • No active infection
  • No other severe (particularly cardiac or pulmonary) diseases or mental disorders that would preclude study participation
  • PRIOR CONCURRENT THERAPY:
  • See Disease Characteristics
  • No prior fludarabine (or other purine analogues) combined with cyclophosphamide and mitoxantrone hydrochloride
  • No prior rituximab, either alone or in combination with chemotherapy

Exclusion

    Key Trial Info

    Start Date :

    July 1 2005

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    March 1 2011

    Estimated Enrollment :

    56 Patients enrolled

    Trial Details

    Trial ID

    NCT00337246

    Start Date

    July 1 2005

    End Date

    March 1 2011

    Last Update

    August 2 2013

    Active Locations (16)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 4 (16 locations)

    1

    Birmingham Heartlands Hospital

    Birmingham, England, United Kingdom, B9 5SS

    2

    Blackpool Victoria Hospital

    Blackpool, England, United Kingdom, FY3 8NR

    3

    Kent and Canterbury Hospital

    Canterbury, England, United Kingdom, CT2 7NR

    4

    St Helier Hospital

    Carshalton, England, United Kingdom, SM5 1AA